In this piece, we will take a look at the 5 healthcare stocks to buy according to Lee Ainslie’s Maverick Capital. If you want to learn more about Mr. Ainslie and his hedge fund, alongside other stocks that he has bought, take a look at 10 Healthcare Stocks to Buy According to Lee Ainslie’s Maverick Capital.
5. Nektar Therapeutics (NASDAQ:NKTR)
Maverick Capital’s Stake Value: $104 million
Percentage of Maverick Capital’s 13F Portfolio: 1.05%
Number of Hedge Fund Holders: 23
Nektar Therapeutics (NASDAQ:NKTR) is an American biotechnology company that is developing products for several diseases. Its products aim to target several types of cancers such as those of the liver, bladder, and urethra. Additionally, it is also developing a treatment for the COVID-19 coronavirus.
Nektar Therapeutics (NASDAQ:NKTR) substantially missed its revenue estimates for fiscal Q3, by posting $24.9 million in the segment. However, the company’s GAAP EPS of -$0.70 beat analyst estimates by $0.10. BTIG slashed its price target for the firm to $54 from $80 in November 2021 following the earnings report, explaining that reduced revenue estimates from a treatment trial influenced the decision.
Mr. Ainslie’s Maverick Capital owned 5.8 million Nektar Therapeutics (NASDAQ:NKTR) shares as the third quarter of this year came to an end. These were worth $104 million and represented 1.05% of its investment portfolio. Insider Monkey’s Q3 2021 poll of 867 hedge funds revealed that 23 owned a stake in the firm.
Nektar Therapeutics (NASDAQ:NKTR)’s largest investor after Maverick Capital is Stephen Dubois’ Camber Capital Management who owns 3.7 million shares worth $67 million.
4. TG Therapeutics, Inc. (NASDAQ:TGTX)
Maverick Capital’s Stake Value: $109 million
Percentage of Maverick Capital’s 13F Portfolio: 1.11%
Number of Hedge Fund Holders: 23
TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company whose products cover several types of leukemias and autoimmune diseases.
Maverick Capital owned a $109 million stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during 2021’s third quarter. This was through holding 3.2 million shares and it represented 1.11% of the firm’s portfolio. An Insider Monkey survey of 867 hedge funds for the same time period revealed that 23 funds owned the company’s shares.
For its fiscal Q3, TG Therapeutics, Inc. (NASDAQ:TGTX) sorely disappointed analysts as it missed estimates for revenue by a mile and failed to meet them for GAAP EPS as well. The company’s $2 million revenue for the quarter missed estimates by $0.94 million. In December 2021, Evercore ISI reduced the company’s price target to $36 from $55, citing worries about a potential Food and Drug Administration (FDA) advisory committee concerns for the company’s drug.
Peter Kolchinsky’s RA Capital Management is TG Therapeutics, Inc. (NASDAQ:TGTX)’s largest investor. It has a $136 million stake in the company through 4 million shares.
3. Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Maverick Capital’s Stake Value: $140 million
Percentage of Maverick Capital’s 13F Portfolio: 1.41%
Number of Hedge Fund Holders: 17
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is developing treatments for patients suffering from cancer, immune system, and viral diseases. Its medicines target solid tumors, hematologic malignancies, and multiple sclerosis, among others.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) raked in $5 million in revenue and -$0.90 in GAAP EPS for its fiscal Q3, beating analyst estimates for both. Stifel reduced its price target to $27 from $30 in October 2021.
Mr. Ainslie’s hedge fund had a stake of $140 million in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) through holding 7.8 million shares. It represented 1.41% of its portfolio during Q3 2021. During the same time period, 17 of the 867 hedge funds polled by Insider Monkey also held a stake in the medical firm.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA)’s largest investor is Seth Klarman’s Baupost Group who owns 8.4 million shares worth $151 million.
2. Seer, Inc. (NASDAQ:SEER)
Maverick Capital’s Stake Value: $187 million
Percentage of Maverick Capital’s 13F Portfolio: 1.88%
Number of Hedge Fund Holders: 11
Seer, Inc. (NASDAQ:SEER) is a backend life sciences company that aims to let its customers extract information from biological systems. Its products cover several areas such as proteomics which is the large-scale study of proteins and their constituent structures.
As Q3 2021 came to an end, Maverick Capital owned 5.4 million Seer, Inc. (NASDAQ:SEER) shares in a $187 million stake constituting 1.88% of its portfolio. Insider Monkey’s survey of 867 hedge funds for the third quarter of this year revealed that 11 funds held a stake in the company.
Seer, Inc. (NASDAQ:SEER)’s revenue and GAAP EPS for its fiscal Q3 stood at $2 million and -$0.30, respectively, as it only beat revenue estimates.
Seer, Inc. (NASDAQ:SEER)’s largest investor after Maverick Capital is Efrem Kamen’s Pura Vida Investments who owns 857,306 shares worth $29 million.
1. Centene Corporation (NYSE:CNC)
Maverick Capital’s Stake Value: $256 million
Percentage of Maverick Capital’s 13F Portfolio: 2.58%
Number of Hedge Fund Holders: 50
Centene Corporation (NYSE:CNC) is an American healthcare company that provides services to uninsured and underinsured individuals globally. Its services cover Medicaid users and its health plans cover several types of coverage such as therapy, dental care, vision care, and primary and specialty physicals.
Centene Corporation (NYSE:CNC) had a strong third fiscal quarter which saw it beat revenue and non-GAAP EPS analyst estimates by posting $32.4 billion and $1.26 in the metrics, respectively. Deutsche Bank raised the company’s price target to $84 from $80 in December 2021, appreciating the company’s recent corporate governance policies.
Mr. Ainslie’s hedge fund owned 4 million Centene Corporation (NYSE:CNC) shares for the third quarter of this year. This stake was worth $256 million and represented 2.58% of its portfolio. Insider Monkey’s Q3 2021 survey of 867 hedge funds revealed that 50 owned the company’s shares.
Andreas Halvorsen’s Viking Global is Centene Corporation (NYSE:CNC)’s largest investor through a $615 million stake bought through 9.8 million shares.
You can also take a peek at the 10 Best Robinhood Stocks Under $20 and Harvard University Stock Portfolio: 8 Latest Stock Picks.
